Immutep LtdASX: IMM

Positive results in TACTI-003 for 1L HNSCC cohort B patients

· Issued by Immutep Ltd

Filed with ASX · · 3 pages · English

Summary by 6ix AI

The combination of eftilagimod alfa and KEYTRUDA achieved a notable response rate and a high complete response rate among evaluable patients. The treatment demonstrated durability, with over half of the patients receiving therapy for at least six months and no new safety signals observed. Immutep plans to discuss the promising results with regulatory agencies due to the high unmet medical need in this patient population.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Immutep Ltd on 6ix

In the deck

Story so far

Earlier from Immutep

Later from Immutep

All Immutep news releases